Cantor Fitzgerald Estimates CAPR FY2026 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the biotechnology company will earn ($1.12) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $30.00 target price on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. During the same quarter in the prior year, the company earned ($0.31) earnings per share.

CAPR has been the topic of several other reports. Wall Street Zen cut Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday, March 17th. Finally, Roth Capital started coverage on shares of Capricor Therapeutics in a research note on Tuesday, May 20th. They set a "buy" rating and a $31.00 target price for the company. One analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $35.50.

Capricor Therapeutics Stock Up 3.8%

NASDAQ CAPR traded up $0.51 on Tuesday, hitting $13.89. The company's stock had a trading volume of 1,384,109 shares, compared to its average volume of 1,785,653. The company's 50-day moving average is $10.39 and its 200 day moving average is $12.85. The firm has a market cap of $634.45 million, a PE ratio of -13.10 and a beta of 0.84. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40.

Institutional Trading of Capricor Therapeutics

Hedge funds have recently modified their holdings of the stock. Summit Investment Advisors Inc. boosted its stake in Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after purchasing an additional 2,947 shares during the period. Virtus ETF Advisers LLC bought a new position in shares of Capricor Therapeutics during the 4th quarter worth about $68,000. AlphaQuest LLC acquired a new stake in shares of Capricor Therapeutics in the 4th quarter valued at about $78,000. Finally, New York State Common Retirement Fund increased its position in Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after buying an additional 5,000 shares in the last quarter. Institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.